We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed (ABMD) Scores a Strong Buy Right Now: Here's How
Read MoreHide Full Article
Headquartered in Danvers, Abiomed, Inc. is engaged in developing, manufacturing and marketing medical products, designed to assist or replace the pumping function of a failing heart. The company has rallied 15.6% over the last three months, ahead of the S&P 500’s 4.4% gain and Zacks categorized Medical - Instruments sub-industry's 11.2%. The stock has a market cap of $6.35 billion. The company’s five-year historical growth rate is also favorable at 83.4% as compared to 2.8% of the S&P 500 index and 9.1% of the broader industry.
With solid prospects, this Zacks Rank #1 (Strong Buy) stock is an attractive pick at present. Let’s find out whether the recent positive trend is a sustainable one.
Abiomed has a positive earnings surprise of 8.1% for the last four quarters. Also, it has a long-term expected earnings growth rate of 32.5%.
The market is upbeat about a study unveiled recently by Abiomed which showed that the use of hemodynamic support with Impella 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) reduces the risk of acute kidney injury even for patients with preexisting kidney diseases and low ejection fraction.
The introduction of the company’s third-generation Impella CP heart pump last month also drove the stock price significantly. This new technology offers features for optimal care during a percutaneous coronary intervention (PCI) in high-risk patients known as a Protected PCI and for patients treated with Impella heart pumps in the ICU.
Also, the company recently announced the enrollment of the first patient under the FDA-approved study, STEMI Door to Unloading, evaluating Impella CP system in acute myocardial infarction. This has driven market sentiments.
As the release of financial results for the first quarter of fiscal 2018is round the corner, a strong fourth-quarter fiscal 2017 performance and company’s promising 2018 revenue guidance which calls for an increase of 25–29% over the prior year has boosted investors’ confidence.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four quarters. The stock has added roughly 13.3% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 25.6% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 34.1% over the last three months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Abiomed (ABMD) Scores a Strong Buy Right Now: Here's How
Headquartered in Danvers, Abiomed, Inc. is engaged in developing, manufacturing and marketing medical products, designed to assist or replace the pumping function of a failing heart. The company has rallied 15.6% over the last three months, ahead of the S&P 500’s 4.4% gain and Zacks categorized Medical - Instruments sub-industry's 11.2%. The stock has a market cap of $6.35 billion. The company’s five-year historical growth rate is also favorable at 83.4% as compared to 2.8% of the S&P 500 index and 9.1% of the broader industry.
With solid prospects, this Zacks Rank #1 (Strong Buy) stock is an attractive pick at present. Let’s find out whether the recent positive trend is a sustainable one.
Abiomed has a positive earnings surprise of 8.1% for the last four quarters. Also, it has a long-term expected earnings growth rate of 32.5%.
The market is upbeat about a study unveiled recently by Abiomed which showed that the use of hemodynamic support with Impella 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) reduces the risk of acute kidney injury even for patients with preexisting kidney diseases and low ejection fraction.
The introduction of the company’s third-generation Impella CP heart pump last month also drove the stock price significantly. This new technology offers features for optimal care during a percutaneous coronary intervention (PCI) in high-risk patients known as a Protected PCI and for patients treated with Impella heart pumps in the ICU.
Also, the company recently announced the enrollment of the first patient under the FDA-approved study, STEMI Door to Unloading, evaluating Impella CP system in acute myocardial infarction. This has driven market sentiments.
As the release of financial results for the first quarter of fiscal 2018is round the corner, a strong fourth-quarter fiscal 2017 performance and company’s promising 2018 revenue guidance which calls for an increase of 25–29% over the prior year has boosted investors’ confidence.
Key Picks
A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Notably, Mesa Laboratories and Edwards Lifesciences sport a Zacks Rank #1, while Align Technology carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four quarters. The stock has added roughly 13.3% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 25.6% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 34.1% over the last three months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>